Selecta Biosciences, Inc.
Data to be featured in two oral presentations and four poster presentations
WATERTOWN, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, power gene therapies and mitigate unwanted immune responses to biologics, today announced six upcoming presentations, including three joint presentations with our partner AskBio, at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually and in-person from May 16-19, 2022 in Washington, D.C. These presentations demonstrate the power of Selectas immune tolerance platform, ImmTOR, in mitigating unwanted immune responses to AAV capsids and potentially enabling gene therapy re-dosing for patients with severe genetic disorders.
We are thrilled to present data demonstrating ImmTORs ability to inhibit anti-AAV antibody formation and potentially enable re-dosing of gene therapies. Excitingly, in a first-in-human clinical trial conducted with our partner AskBio, we demonstrated the ability of ImmTOR to blunt the early immune response to empty AAV8 capsids said Dr. Kei Kishimoto, Ph.D., Chief Scientific Officer of Selecta. Furthermore, we are pleased to showcase results indicating an evolution of our ImmTOR platform is close at hand. Combining ImmTOR with engineered T-reg specific IL-2 mutein (ImmTOR-IL) synergistically enhances the magnitude and durability of mitigation of anti-AAV antibody formation in preclinical studies. We look forward to initiating our Phase 1 clinical trial for the treatment of methylmalonic acidemia, building on these data, and continuing our efforts to help patients overcome autoimmunity and immunogenicity with our precision immune tolerance therapies.
Details and key takeaways from ASGCT presentations are as follows:
Oral Presentations:
Selecta Presentation Title: Mechanisms, Monitoring, and Mitigation of Host Immune Responses to AAV Gene Therapy VectorsSession Title: Immune Responses to Gene TherapyPresenter: Kei Kishimoto, Ph.D., Selecta BiosciencesPresentation Date and Time: Monday, May 16, 2022, 2:20 - 2:45 p.m. ETKey takeaways: General overview of the various ways that the immune response affects the efficacy and safety of AAV gene therapy and development of ImmTOR to mitigate these effects.
Story continues
Selecta & AskBio Presentation Title: Functional Assessment of T Cell Responses to AAV8 Empty Capsids in Healthy VolunteersSession Title: Immune Responses to AAV VectorsAbstract Number: 37Presenter: Shari Gordon, AskBioPresentation Date and Time: Monday, May 16, 2022, 10:30 - 10:45 a.m. ET Key takeaways: This study demonstrates for the first time that empty AAV capsids, a hidden component of all AAV gene therapies, are highly immunogenic in humans.
Poster Presentations:
Selecta Presentation Title: ImmTOR Combined with B Cell-Targeted Therapies Provides Synergistic Activity in Mitigating Anti-AAV Capsid Antibody Responses and Enables Repeated Vector DosingSession Title: Immunological Aspects of Gene Therapy and Vaccines IIPoster: W-255Abstract Number: 1129Presenter: Petr Ilyinskii, Selecta BiosciencesPresentation Date and Time: Wednesday, May 18, 2022, 5:30 - 6:30 p.m. ETKey takeaways: The combination of ImmTOR and B cell-targeted therapies act synergistically to inhibit anti-AAV antibody response to enable repeated dosing, including vectors doses up to 5E13 vg/kg.
Selecta Presentation Title: Combination of ImmTOR Tolerogenic Nanoparticles and IL-2 Mutein Synergistically Inhibits the Formation of Anti-AAV AntibodiesSession Title: Immunological Aspects of Gene Therapy and Vaccines IIPoster: W-256Abstract Number: 1130Presenter: Kei Kishimoto, Ph.D., Selecta BiosciencesPresentation Date and Time: Wednesday, May 18, 2022, 5:30 - 6:30 p.m. ETKey takeaways: ImmTOR-IL, the combination of ImmTOR and Treg-selective IL-2 mutein, show profound synergistic effects on inducing antigen-specific Treg and enable more durable inhibition of anti-AAV antibody response at vectors doses up to 5E13 vg/kg.
Selecta & AskBio Presentation Title: Effect of Tolerogenic ImmTOR Nanoparticles on the Formation of Anti-AAV8 Antibodies in Mice, Nonhuman primates, and Healthy Human VolunteersSession title: Immunological Aspects of Gene Therapy and Vaccines IPoster: Tu-216Abstract Number: 711Presenter: Peter Traber, M.D., Selecta BiosciencesPresentation Date and Time: Tuesday, May 17, 2022, 5:30 - 6:30 p.m. ETKey takeaways: A single dose of ImmTOR is shown to mitigate the early anti-AAV neutralizing antibody response in humans and preclinical studies indicate that antibody inhibition can be sustained with multiple doses of ImmTOR.
Selecta & Askbio Presentation Title: ImmTOR Blunts AAVrh32.33 Capsid-specific Immune Responses in C57BL/6 Albino MiceSession Title: Immunological Aspects of Gene Therapy and Vaccines IPoster: Tu-213Abstract Number: 708Presenter: Md Mahmudul Hasan, AskBioPresentation Date and Time: Tuesday, May 17, 2022, 5:30 - 6:30 p.m. ETKey takeaways: ImmTOR is shown to inhibit capsid-specific CD8 T cell responses, which in human clinical trials have been associated with serum transaminase elevation and loss of transgene expression.
Following the conference, the presentations will be available in the Resources section of Selectas website at http://www.selectabio.com/resources/.
About Selecta Biosciences, Inc.Selecta Biosciences, Inc. is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion and anticipated proceeds of the proposed offering. All such forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to fluctuations in Selectas stock price, changes in market conditions and satisfaction of customary closing conditions related to the offering, as well as the other factors discussed in the Risk Factors section in Selectas most recently filed Annual Report on Form 10-K as well as other risks detailed in Selectas subsequent filings with the Securities and Exchange Commission. There can be no assurance that Selecta will be able to complete the proposed offering on the anticipated terms. All information in this press release is as of the date of the release, and Selecta undertakes no duty to update this information unless required by law.
For Investors:Bruce MackleLifeSci Advisors, LLCPhone: +1-929-469-3859Email: bmackle@lifesciadvisors.com
For Media:Brittany Leigh, Ph.D.LifeSci Communications, LLCPhone: +1-646-751-4366Email: bleigh@lifescicomms.com
- Krystal Biotech Inc (KRYS) Reports Strong Q4 and Full Year 2023 Financial Results - Yahoo Finance - February 27th, 2024
- New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle - CNBC - February 27th, 2024
- 10 gene therapy companies you should know about - Labiotech.eu - February 27th, 2024
- Former Penn employee sues Gene Therapy Program director, alleging 'unethical and illegal conduct' - The Daily Pennsylvanian - February 27th, 2024
- Gene therapy can't cure deafness because it doesn't need to be cured - The Philadelphia Inquirer - February 27th, 2024
- Fetal surgery expert Tippi MacKenzie shifts to in-utero gene therapy - STAT - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - Business Wire - February 27th, 2024
- CU Anschutz Set to Launch Gene Therapy Trials for Heart Disorder - University of Colorado Anschutz Medical Campus - February 27th, 2024
- ICH targets cell and gene therapies, real-world data as topics ripe for harmonization - Regulatory Focus - February 27th, 2024
- Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101 - Business Wire - February 27th, 2024
- Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in ... - GlobeNewswire - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - The Bakersfield Californian - February 27th, 2024
- Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff - STAT - February 27th, 2024
- Ed Silverman on new gene therapies, biosimilars, coffee, and more - STAT - STAT - February 27th, 2024
- Combatting HIV using gene therapy - Drug Target Review - February 27th, 2024
- NCDHHS working with federal government on increasing access to sickle cell disease treatment - WECT - February 27th, 2024
- Cell Therapy Weekly: FDA Approves First Cell Therapy For Solid Tumors - RegMedNet - February 27th, 2024
- Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age ... - Business Wire - February 27th, 2024
- New sickle cell therapy uses gene editing at MUSC | Health | postandcourier.com - The Post and Courier - February 27th, 2024
- Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency - Nature.com - February 18th, 2024
- Gene therapy, blood transfusions, stool monitoring: The Sydneysiders trying to escape death - Sydney Morning Herald - February 18th, 2024
- Not too late to repair: gene therapy improves advanced heart failure in animal model - Baylor College of Medicine | BCM - February 18th, 2024
- Direct Administration of CRISPR-Cas9: Tools for Cell and Gene Therapy - Forbes - February 18th, 2024
- Gene therapy's promise seen in its success for AADC deficiency - AADC News - February 18th, 2024
- First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment - Diagnostic and Interventional Cardiology - February 18th, 2024
- FDA to review expanded use of Sarepta Duchenne gene therapy - Yahoo Finance - February 18th, 2024
- How gene therapy can help treat a rare blood disorder - KUTV 2News - February 18th, 2024
- CRISPR gene therapy Casgevy secures approval in Europe - Pharmaceutical Technology - February 18th, 2024
- FDA Updates for the Week of Feb. 12, 2024: New Approvals, an Extended Review and Goal Dates Set - Managed Healthcare Executive - February 18th, 2024
- First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure - Business Wire - February 18th, 2024
- Lisa Jarvis: A cure for some kinds of hearing loss? Gene therapies are getting closer - St. Paul Pioneer Press - February 18th, 2024
- Spinal Muscular Atrophy Market: Navigating Therapeutic Advances towards USD 5.6 Billion by 2034, with a CAGR of ... - Yahoo Finance - February 18th, 2024
- Crispr Therapeutics' Gene Therapy Wins EU Approval - TipRanks.com - TipRanks - February 18th, 2024
- Revolutionizing Gene Therapy: A Novel Technique for In Vivo CAR T Cells - Medriva - February 18th, 2024
- How Stella Vnook is 'infusing innovation' into cell therapies with Likarda's technology - BioPharma-Reporter.com - February 18th, 2024
- Using cancer's 'superpower' to boost T-cell therapies in mice - FierceBiotech - February 18th, 2024
- Parkinson's Disease Patient Identification and Education Will Need to Improve When New Disease Modifying ... - Yahoo Finance - February 18th, 2024
- CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? - Yahoo Finance - February 18th, 2024
- Gene Therapy: A Ray of Hope for Heart Failure Treatment | Health News - Medriva - February 18th, 2024
- Gene therapy trials restore hearing to children born deaf - The Hill - February 2nd, 2024
- Early Trial Success for Inherited Deafness Gene-Therapy - RegMedNet - February 2nd, 2024
- Sickle cell gene therapy first focus of Medicaid pay model - Modern Healthcare - February 2nd, 2024
- Beyond chemotherapy: Navigating the promise and perils of CAR-T therapy in pediatric cancer - BioPharma-Reporter.com - February 2nd, 2024
- Angiodema: Gene therapy blocks painful hereditary disorder - BBC - February 2nd, 2024
- FDA: Genome editing therapies may use accelerated approval pathway - Regulatory Focus - February 2nd, 2024
- CRISPR tech treats severe hereditary condition successfully - Interesting Engineering - February 2nd, 2024
- Gene Therapy Restores Hearing in Small Trial for Kids With Hereditary Deafness - Technology Networks - February 2nd, 2024
- Gene-based therapy may slow development of life-threatening heart condition - Medical Xpress - February 2nd, 2024
- Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum ... - Business Wire - February 2nd, 2024
- Replacing the PKP2 gene prolongs survival in ARVC patients - Drug Target Review - February 2nd, 2024
- Cell and gene therapies top pharmaceutical industry trend to watch for 2024 - Pharmaceutical Technology - February 2nd, 2024
- Gene Therapy Restores Hearing in Children with Hereditary Deafness - The Hearing Review - February 2nd, 2024
- 2 Dutch among 10 "functionally cured" of hereditary swelling disease by new gene therapy - NL Times - February 2nd, 2024
- FDA publishes final industry guidance for CAR-T and gene therapies - PMLiVE - February 2nd, 2024
- Gene therapy cures hereditary deafness in two people - Advanced Science News - February 2nd, 2024
- Hearing Restored in Deaf Children in Gene Therapy Clinical Trial - Securities.io - February 2nd, 2024
- Vivet Therapeutics Receive 4.9 Million to Advance Development of Gene Therapy - European Pharmaceutical Manufacturer - February 2nd, 2024
- Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on ... - GlobeNewswire - February 2nd, 2024
- Allogene parks Notch CARs, leaving one on the road - FierceBiotech - February 2nd, 2024
- Experimental gene therapy allows kids with inherited deafness to hear - The Associated Press - January 25th, 2024
- Gene-therapy breakthrough allows congenitally deaf children to hear Harvard Gazette - Harvard Gazette - January 25th, 2024
- Gene therapies restore hearing in several kids with inherited deafness - Livescience.com - January 25th, 2024
- Boy born deaf can hear for the first time thanks to a gene therapy procedure - NBC 6 South Florida - January 25th, 2024
- Gene therapy restores hearing in children with hereditary deafness - Medical Xpress - January 25th, 2024
- Children's Hospital of Philadelphia Performs First in U.S. Gene Therapy Procedure to Treat Genetic Hearing Loss - PR Newswire - January 25th, 2024
- Children's Hospital of Philadelphia uses gene therapy to help 11-year-old boy hear for 1st time - WPVI-TV - January 25th, 2024
- Breakthrough gene therapy treatment restores hearing in children born deaf - The Independent - January 25th, 2024
- Gene Therapy Administered Via Virus Cures Deafness in 11-Year-Old Boy - Futurism - January 25th, 2024
- 11-Year-Old Boy Hears For First Time Ever Thanks To Gene Therapy Breakthrough - IFLScience - January 25th, 2024
- Gene Therapy Deafness | National | caledonianrecord.com - The Caledonian-Record - January 25th, 2024
- Sickle cell gene therapy to be covered by Blue Cross insurers - Modern Healthcare - January 25th, 2024
- Experimental gene therapy allows kids with inherited deafness to hear - Jackson Hole News&Guide - January 25th, 2024
- Gene therapy allows 11-year-old boy to hear for the first time - Latest From ITV News - ITVX - January 25th, 2024
- Experimental Gene Therapy Allows Kids With Inherited Deafness To Hear - Southern Minnesota News - January 25th, 2024
- Joint US-China gene therapy trials restore hearing in 5 kids, a first - Interesting Engineering - January 25th, 2024
- Gene Therapy Deafness | Nation | The Daily News - Galveston County Daily News - January 25th, 2024
- In Draft Guidance for Cell and Gene Therapy Industry, FDA Broadens its Approach to Product Potency - Precision Medicine Online - January 25th, 2024
- Gene therapy helps restore hearing in children with hereditary deafness - Shropshire Star - January 25th, 2024
- Gene therapy breakthrough enables deaf boy to hear for the first time - The Week - January 25th, 2024
- FDA eyes collaborative review pilot for gene therapies - Regulatory Focus - January 17th, 2024